Diversity in clinical trials can positively impact patient care and outcomes, particularly among minority populations, Anita ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

Johnson & Johnson said the first clinical data from its ongoing Phase 1b study of JNJ-4496, a chimeric antigen receptor T-cell therapy, shows encouraging potential in treating large B-cell lymphoma, ...

Ola Landgren, MD, PhD, shares ADVANCE trial results, which show that adding daratumumab to carfilzomib-lenalidomide-dexamethasone (DKRd) improves outcomes in newly diagnosed multiple myeloma.

For many patients grappling with serious health conditions like ALS (Amyotrophic Lateral Sclerosis), the search for effective ...

Medpace has a strong financial position with high profit margins and low debt. Click here to read more about MEDP stock.

Gilead Sciences, Inc. GILD announced that the FDA has placed a clinical hold on studies on pipeline candidates, GS-1720 and/or GS-4182, for the treatment of HIV. GS-1720 is an investigational ...

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, unveils AI agents at GTC ...

While the company is showing early signs of recovery and margin improvement, a high valuation means risks remain.

OCU400 is Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP). The OCU400 (AAV5-h NR2E3) gene therapy platform delivers the nuclear hormone receptor NR2E3 to the retina and retinal ...

In a phase 3 clinical trial, chronic night driving impairment in patients who underwent keratorefractive procedures improved ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 ...